Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non–Q-wave myocardial infarction
| Autor: | Marco Tubaro, Furio Colivicchi, Fabrizio Ammirati, Nicola Montefoschi, Vincenzo Guido, Massimo Santini, Antonio Varveri |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Hypercholesterolemia Myocardial Infarction Revascularization Coronary artery disease Angina Recurrence Internal medicine Atorvastatin medicine Humans Pyrroles Angina Unstable Myocardial infarction Aged Ejection fraction business.industry Unstable angina Anticholesteremic Agents Cardiovascular Agents Middle Aged medicine.disease Survival Rate Heptanoic Acids Heart failure Cardiovascular agent Cardiology Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| Zdroj: | The American Journal of Cardiology. 90:872-874 |
| ISSN: | 0002-9149 |
| Popis: | This clinical investigation was designed and undertaken to test the hypothesis that the addition of high-dose atorvastatin (80 mg/day) to conventional medical treatment early after either unstable angina pectoris (UAP) or non–Q-wave acute myocardial infarction (AMI) could reduce ischemic recurrences. All patients consecutively admitted to our institution between January 1999 and July 2001 for UAP or non–Q-wave AMI were prospectively screened for inclusion in the study. In all cases the diagnosis of UAP or non–Q-wave AMI was made in accordance with previously reported criteria. 1 To be enrolled in the trial, patients were required to meet the following criteria: (1) angiographic evidence of severe and diffuse coronary artery disease, that was not amenable to direct revascularization by coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, as determined by a cardiac surgeon and an interventional cardiologist during the index admission; (2) objective evidence of symptomatic reversible myocardial ischemia (0.1 mV ST-segment depression on the electrocardiogram) at a low exercise workload (4 METs) while receiving medical treatment (2 antianginal medications at maximal tolerated doses), as assessed by treadmill ergometry (Bruce’s protocol) before discharge; and (3) left ventricular ejection fraction 35%. Exclusion criteria were the presence of congestive heart failure, the need for continuous use of intravenous antianginal medications, and the presence of any major concurrent illness. The study was planned as an open-label, prospective, randomized, controlled trial with parallel groups. Before enrollment, all patients were receiving maximal conventional combination therapy (nitrates, calcium antagonists, and blockers), including 2 medications at maximal tolerated doses in all cases. All patients provided informed consent to take part in the investigation. At discharge from the hospital, included patients |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect